Skip to main content

Advertisement

Table 1 LCMRglu in efferent brain regions of control and CRFR2-null mice in response to 5-HT 1A R or 5-HT 2 R agonist

From: Increased anxiety in corticotropin-releasing factor type 2 receptor-null mice requires recent acute stress exposure and is associated with dysregulated serotonergic activity in limbic brain areas

  Control CRFR2-null Control CRFR2-null
  Saline 8-OH-DPAT % Saline 8-OH-DPAT % Saline DOI % Saline DOI %
Neocortex             
Frontal 46 ± 3 33 ± 3* −28 47 ± 3 42 ± 3* −21 a 47 ± 3 38 ± 2* −19 45 ± 2 30 ± 2* −33 a, b
Anterior cingulate 48 ± 3 35 ± 2* −27 49 ± 2 39 ± 4* −35 a 50 ± 3 40 ± 2* −15 51 ± 3 34 ± 2* −33 a
Prefrontal 47 ± 3 35 ± 3* −26 47 ± 3 42 ± 2 −6 a 50 ± 3 39 ± 3* −22 50 ± 3 30 ± 2* −40 a
Somatosensory 55 ± 2 33 ± 4* −40 51 ± 4 45 ± 3* −22 a 56 ± 2 53 ± 3 −5 55 ± 4 44 ± 3* −20 a
Parietal 53 ± 2 35 ± 2* −34 50 ± 4 43 ± 3 −21 a 55 ± 2 45 ± 1* −18 54 ± 3 37 ± 2* −31 a, b
Hippocampus             
Subiculum 40 ± 3 26 ± 3* −35 45 ± 3 23 ± 3* −49 a 42 ± 2 43 ± 3 2 43 ± 3 33 ± 3* −23
Dentate gyrus 26 ± 3 16 ± 3* −38 30 ± 2 15 ± 3* −50 a 28 ± 3 18 ± 2* −36 27 ± 3 16 ± 2* −14 a
CA1 37 ± 3 22 ± 4* −41 38 ± 3 16 ± 2* −58 a 36 ± 3 26 ± 3* −28 37 ± 2 26 ± 2* −30 a
CA2 35 ± 3 20 ± 3* −43 36 ± 3 19 ± 2* −47 a 35 ± 3 34 ± 3 −3 36 ± 3 29 ± 2* −19
CA3 38 ± 2 20 ± 2* −47 41 ± 2 17 ± 2* −58 a 36 ± 2 28 ± 3 −22 36 ± 2 22 ± 3* −39 a
Extrapyramidal areas             
Medial striatum 43 ± 3 33 ± 2* −23 42 ± 3 39 ± 3 −7 a 45 ± 3 34 ± 2* −24 46 ± 3 29 ± 2* −37 a
Lateral striatum 46 ± 3 29 ± 3* −37 44 ± 3 41 ± 3 −7 c 46 ± 4 30 ± 3* −35 48 ± 4 31 ± 3* −35 a
Globus pallidus 33 ± 2 20 ± 2 −39 32 ± 2 33 ± 2 −3 a, b, c 32 ± 2 30 ± 2 −6 35 ± 2 23 ± 3* −34 a, c
Substantia nigra 30 ± 3 20 ± 1* −27 27 ± 3 25 ± 4 −7 28 ± 4 30 ± 2 7 28 ± 2 18 ± 4 −36
Limbic areas             
Medial septal nucleus 41 ± 3 30 ± 2* −27 39 ± 3 22 ± 2* −44 a 45 ± 2 31 ± 2* −31 48 ± 3 30 ± 2* −38 a
Lateral septal nucleus 38 ± 3 27 ± 3* −29 40 ± 2 18 ± 2* −55 a, c 37 ± 3 28 ± 3 −24 40 ± 4 27 ± 3* −33 a
Bed nucleus of the stria terminalis 27 ± 4 18 ± 2* −33 31 ± 2 16 ± 3* −48 a 30 ± 4 20 ± 2 −33 30 ± 2 18 ± 3* −40 a
Basolateral amygdala 36 ± 3 26 ± 3* −28 36 ± 2 15 ± 2* −58 a, b, c 38 ± 2 27 ± 4 −29 38 ± 2 24 ± 4* −37 a
Central amygdala 26 ± 2 20 ± 2* −23 25 ± 3 15 ± 2* −40 a 25 ± 2 17 ± 2 −32 24 ± 3 15 ± 2* −38 a
  1. Local cerebral glucose utilization (LCMRglu), shown as mean ± SEM and percentage change in LCMRglu in 8-OH-DPAT or DOI compared with saline-treated mice. n = 8. aMain effect of drug; bmain effect of genotype, cgenotype X drug interaction in 2-way ANOVA, where critical F(1,28) value was 4.20 for P ≤ 0.05. *P < 0.05 vs saline in post-hoc analysis.